The FDA’s Oncologic Drugs Advisory Committee on Wednesday voted 14 to 6 in favor of the efficacy of US WorldMeds’ potential therapy to reduce the risk of relapse in pediatric patients with high-risk neuroblastoma.
The vote sets up a tricky and potentially precedent-setting decision for FDA, as adcomm members questioned…
Click here to view original post
